NCT04930315已完成2 期
SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Technically Resectable Hepatocellular Carcinoma
Zhejiang University1 个研究点 分布在 1 个国家目标入组 78 人开始时间: 2021年9月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 78
- 试验地点
- 1
- 主要终点
- 1-year tumor recurrence-free rate
研究概览
简要总结
The purpose of this study was to compare the efficacy and safety of camrelizumab + apatinib mesylate neoadjuvant therapy combined with camrelizumab adjuvant therapy and camrelizumab adjuvant therapy alone in patients with technically resectable hepatocellular carcinoma.
详细描述
The purpose of this study was to compare the efficacy and safety of camrelizumab + apatinib mesylate neoadjuvant therapy combined with camrelizumab adjuvant therapy and camrelizumab adjuvant therapy alone in patients with technically resectable hepatocellular carcinoma. There are two groups:
- Neoadjuvant and adjuvant group: (1) Preoperative：Camrelizumab ：200mg, iv, d1, q2w, 4 cycles；apatinib：250mg, po, qd, q2w, 3 cycles; (2) Operation; (3) Postoperation 4-8 weeks，Camrelizumab ：200mg, iv, d1, q2w, Up to 8 cycles.
- Adjuvant group: (1) Operation; (2) Postoperation 4-8 weeks，Camrelizumab ：200mg, iv, d1, q2w, Up to 12 cycles.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18-70 years old, both genders.
- •Histologically confirmed diagnosis of HCC or strictly consistent with the clinical diagnostic criteria for HCC according to AASLD guideline
- •BCLC stage was B / C, or CNLC stage was IIa-IIIb, but technically resectable (the number of tumors was less than 7, accompanied by ipsilateral portal vein or hepatic vein tumor thrombus formation, but no main portal vein, contralateral portal vein, contralateral hepatic vein or inferior vena cava tumor thrombus, no extrahepatic metastasis, estimated residual liver volume > 30% [if patients with liver fibrosis, residual liver volume > 40%])
- •At least one measurable lesion that meet the mRECIST standard, and the lesion has not received radiotherapy, or local treatments
- •Child-Pugh score: A grade
- •ECOG PS 0-1 points.
- •The function of vital organs meets the following requirements (excluding the use of any blood component and cell growth factor within 14 days) :
- •Neutrophils ≥1.5×109/L
- •Platelet count ≥100×109/L
- •Hemoglobin ≥90g/L
- •Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal value (ULN)
- •AST or ALT levels ≤ 1.5 times the upper limit of normal value (ULN);
- •Serum albumin ≥ 30 g / L
- •Thyroid stimulating hormone (TSH) ≤ ULN
- •Subjects who did not receive anticoagulant therapy: International standardized ratio INR or Partial thromboplastin time APTT≤1.5×ULN; subjects received prophylactic anticoagulant therapy, INR≤1.5×ULN and APTT ≤ ULN within 14 days before the start of study treatment;
- •Serum creatinine (SCr) ≤ 1.5 times upper limit of normal value (ULN) and creatinine clearance ≥60 ml/min (Cockcroft-Gault formula)
- •If HBsAg (+) and / or anti HCV (+), according to the results of HBV DNA or HCV RNA detection, antiviral therapy should be carried out according to the standard
- •Women of childbearing age should with negative serum or urine pregnancy tests within 14 days prior to study inclusion and who must be non-lactating, and patient should agree to use contraceptives (such as intrauterine devices, contraceptives or condoms) during and within 60 days of the end of medication
- •Males with partner of childbearing age should agree to use contraceptives during the study period and for 120 days after the end of the study period;
- •Subjects have good compliance and cooperate with the follow-up.
排除标准
- •Known hepatobiliary cell carcinoma, mixed cell carcinoma and fibre-lamellar cell carcinoma;
- •Co-infection with hepatitis B and C, or co-infection with hepatitis B and D
- •Active malignancies other than HCC within 5 years or concurrently, except for cured basal cell carcinoma of the skin and carcinoma in situ of the cervix and papillary thyroid cancer
- •Subjects has received radical hepatectomy, systemic anticancer therapy for HCC (mainly including systemic chemotherapy, molecular targeted therapy and CTLA-4, PD-1 / PD-L1 monoclonal antibody immunotherapy) and local treatment for liver, including TACE, TAE, tare or local ablation, radiotherapy, etc
- •Presence of the following within 3 months prior to study entry: myocardial infarction, severe unstable angina, NYHA class 2 or higher cardiac insufficiency, poorly controlled arrhythmias, symptomatic congestive heart failure, cerebrovascular accident.
- •Having hypertension that cannot be well controlled by antihypertensive drug therapy (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg);Previous history of hypertension crisis or hypertensive encephalopathy;
- •Active pulmonary tuberculosis or pulmonary tuberculosis history
- •Subject has any active autoimmune disease or history of autoimmune disease (such as, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism; Subjects with vitiligo or childhood asthma have been completely relieved and may be included as adults without any intervention;Asthma requiring medical intervention with bronchodilators will not be included);
- •Interstitial lung disease history or non-infectious pneumonia requiring oral or intravenous steroid therapy
- •Subjects are receiving immunosuppressive, or systemic, or absorbable local hormone therapy for immunosuppression purposes (>10mg/ day prednisone or other therapeutic hormones) and continue to receive such therapy within 2 weeks prior to enrollment;
- •Abnormal coagulation (INR > 1.5 or APTT > 1.5 x ULN) with bleeding tendency or on thrombolytic or anticoagulant therapy
- •The presence of clinically significant bleeding symptoms or a definite bleeding tendency within 3 months prior to study entry, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, fecal occult blood +++ or more at baseline, or vasculitis. Gastroscopy was performed if fecal occult blood was positive at baseline, or if it was an observable bloody stool. If gastroscopy indicated severe esophageal varices, it could not be included
- •Known hypersensitivity to apatinib, camrelizumab or drug excipients; or severe allergic reactions to other monoclonal antibodies
- •Subject has active infection or unexplained fever of >38.5 degrees during screening and before first administration (subject's fever due to tumor can be enrolled according to the investigator's judgment);
- •Grade III or above myelosuppression (WBC < 1.9) × 109 / L, hemoglobin lower than 79 g / L, platelet lower than 49 g / L × 109/L）
- •Severe liver dysfunction, serum albumin less than 28 g/L, or serum bilirubin more than 50 μmol/L, or serum alanine transferase was 1.5 times higher than normal
- •HIV positive (HIV 1/2 anti-body)
- •Live vaccine is administered less than 30 days before or possibly during the study period;
- •The subject has a known history of psychotropic substance abuse, alcohol abuse or drug abuse;
- •Researchers think that should be left out in this study, the researchers determine, for example, the subjects have other factors that may result in this study were forced to midway termination, such as, other serious disease (including mental illness) need to merge treatment, there are serious abnormal laboratory examination, accompanied by factors such as family or society, will affect the safety of the subjects, or information and the collection of the sample.
研究组 & 干预措施
adjuvant group
Active Comparator
Operation Postoperation 4-8 weeks，Camrelizumab ：200mg, iv, d1, q2w, Up to 12 cycles
干预措施: Camrelizumab (Drug)
neoadjuvant and adjuvant group
Experimental
Preoperative：Camrelizumab ：200mg, iv, d1, q2w, 4 cycles；apatinib：250mg, po, qd, q2w, 3 cycles Operation Postoperation 4-8 weeks，Camrelizumab ：200mg, iv, d1, q2w, Up to 8 cycles
干预措施: Apatinib Mesylate (Drug)
neoadjuvant and adjuvant group
Experimental
Preoperative：Camrelizumab ：200mg, iv, d1, q2w, 4 cycles；apatinib：250mg, po, qd, q2w, 3 cycles Operation Postoperation 4-8 weeks，Camrelizumab ：200mg, iv, d1, q2w, Up to 8 cycles
干预措施: Camrelizumab (Drug)
结局指标
主要结局
1-year tumor recurrence-free rate
时间窗: Up to one years
The proportion of patients who had tumor recurrence (local, regional or distant) or death within 1 year after surgery, whichever occurred first
1-year event-free survival rate
时间窗: Up to one years
The proportion of patients who had tumor progression, tumor recurrence (local, regional or distant) or death within 1 year after surgery, whichever occurred first
次要结局
- 1-year survival rate(Up to 1 years)
- R0 resection rate(Up to 2 years.)
- Pathological Complete Response (pCR)(Up to 2 years.)
- Overall survival (OS)(Up to 2 years.)
- Recurrence free survival (RFS)(Up to 1 years)
- Surgical resection rate(Up to 2 years.)
- Major pathological response (MPR)(Up to 2 years.)
- Adverse events(Safety evaluation was done continuously during treatment by using CTCAE 5.0)
- Recurrence free survival (RFS)(Up to 2 years)
- Event-free survival(Upto 2 years)
研究者
TingBo Liang
The chairman of the First Affiliated Hospital of Zhejiang University School of Medicine
Zhejiang University
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung CancerNSCLCNCT04506242Cancer Institute and Hospital, Chinese Academy of Medical Sciences74
已完成
2 期
Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric CancerAdvanced Gastric CancerNCT04195828Fujian Medical University106
Unknown
1 期
Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric CancerLocally Advanced or Metastatic Gastric AdenocarcinomaNCT04572542The First Affiliated Hospital of Xiamen University46
招募中
不适用
A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaNCT05409482Meng Chao Hepatobiliary Hospital of Fujian Medical University300
招募中
不适用
Camrelizumab Combined With Apatinib MesylateSolid TumorNCT05380986Henan Cancer Hospital500